Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

Viking Therapeutics reported strong Phase 2 VENTURE-Oral Dosing trial results for its obesity drug VK2735, an oral GLP-1/GIP dual agonist, demonstrating up to a 12.2% mean body weight reduction over 13 weeks, with up to 97% of patients achieving ≥5% weight loss and 80% achieving ≥10%. The drug showed a safe and well-tolerated profile with no observed plateau in weight loss, positioning it as a significant oral contender in the obesity market, particularly following recent less impactful data from a competitor's oral GLP-1. Despite these positive clinical outcomes, VKTX stock experienced a premarket decline of over 19%.

Analysis

Viking Therapeutics (VKTX) reported statistically significant and clinically meaningful results from its Phase 2 VENTURE trial for the oral obesity drug, VK2735. The dual GLP-1/GIP agonist achieved its primary endpoint, demonstrating a placebo-adjusted mean body weight reduction of up to 10.9% (12.2% total) over 13 weeks. The drug's efficacy is further supported by high responder rates, with up to 80% of participants achieving at least 10% weight loss, and a favorable safety profile with most adverse events being mild to moderate. Critically, no plateau in weight loss was observed at the 13-week mark, suggesting potential for greater efficacy over longer treatment periods. These results position VK2735 as a strong competitor to Eli Lilly's (LLY) oral candidate, orforglipron, which previously showed a 12.4% weight reduction. Despite the strong clinical data, which garnered a highly positive sentiment score of 0.85, VKTX stock experienced a sharp 19.22% premarket decline, indicating a significant disconnect between the trial's success and immediate market sentiment, possibly due to a 'sell-the-news' reaction or expectations that may have been benchmarked against the company's more potent subcutaneous formulation.

Key Decisions for Investors

• Investors should analyze the stark divergence between the positive Phase 2 clinical data and the negative stock reaction, to determine if the sell-off presents a value opportunity or a fundamental repricing of market expectations.
• Given that VK2735's efficacy now appears highly competitive with Eli Lilly's oral candidate, positions in both VKTX and LLY should be re-evaluated in the context of an intensifying oral obesity drug race.
• Pay close attention to future catalysts, particularly longer-duration trial data, as the absence of a weight-loss plateau at 13 weeks is a key indicator for potentially superior long-term efficacy.
• Despite the favorable safety report, the complete adverse event profile remains a critical factor to monitor, as tolerability will be a key differentiator in this competitive market.